S
SCYNEXIS, Inc. (SCYX)
NCM – Real Time Price. Currency in USD
0.78
-0.04 (-5.35%)
At close: May 12, 2026, 4:00 PM EDT
0.80
+0.02 (2.56%)
After-hours: May 12, 2026, 7:20 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.78
-0.04 (-5.35%)
At close: May 12, 2026, 4:00 PM EDT
0.80
+0.02 (2.56%)
After-hours: May 12, 2026, 7:20 PM EDT
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Name | Position |
|---|---|
| Dr. David Gonzalez Angulo M.D. | CEO, President & Director |
| Mr. Ivor Macleod C.P.A., M.B.A. | Chief Financial Officer |
| Mr. Scott Sukenick J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Daniella Gigante | Vice President of Human Resources & Information Technology |
| Date | Type | Document |
|---|---|---|
| 2026-05-01 | S-3 | d20395ds3.htm |
| 2026-04-30 | DEF 14A | ny20069793x2_def14a.htm |
| 2026-04-27 | DEF 14A | ny20069828x2_def14a.htm |
| 2026-04-20 | PRE 14A | ny20069793x1_pre14a.htm |
| 2026-04-17 | PRE 14A | ny20069828x1_pre14a.htm |
| 2026-03-31 | 8-K | d122408d8k.htm |
| 2026-03-04 | 10-K | scyx-20251231.htm |
| 2025-11-05 | 10-Q | scyx-20250930.htm |
| 2025-10-15 | 8-K | scyx-20251014.htm |
| 2025-08-13 | 10-Q | scyx-20250630.htm |